{"id":"tildrakizumab-prefilled-syringe","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2108681","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tildrakizumab binds to the p19 subunit of IL-23, a key cytokine involved in the pathogenesis of psoriasis and other inflammatory skin conditions. By inhibiting IL-23 signaling, it suppresses the differentiation and activation of pathogenic T cells, particularly Th17 cells, thereby reducing skin inflammation and improving clinical outcomes in psoriasis.","oneSentence":"Tildrakizumab is a monoclonal antibody that selectively blocks interleukin-23 (IL-23) to reduce inflammatory immune responses in the skin.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:12:45.120Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe plaque psoriasis"}]},"trialDetails":[{"nctId":"NCT05110313","phase":"PHASE4","title":"Effects of Tildrakizumab on Epigenetic Age","status":"COMPLETED","sponsor":"Carlos Wambier","startDate":"2022-04-08","conditions":"Psoriasis, Aging, Epigenetic Disorder","enrollment":30},{"nctId":"NCT05390515","phase":"PHASE4","title":"Psoriatic Immune Response to Tildrakizumab","status":"UNKNOWN","sponsor":"University of California, San Francisco","startDate":"2022-09-01","conditions":"Psoriasis Vulgaris","enrollment":10},{"nctId":"NCT04465292","phase":"EARLY_PHASE1","title":"The Effects of Tildrakizumab in Treatment of Bullous Pemphigoid","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2020-09-01","conditions":"Pemphigoid, Bullous","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Tildrakizumab Prefilled Syringe","genericName":"Tildrakizumab Prefilled Syringe","companyName":"Brigham and Women's Hospital","companyId":"brigham-and-women-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tildrakizumab is a monoclonal antibody that selectively blocks interleukin-23 (IL-23) to reduce inflammatory immune responses in the skin. Used for Moderate to severe plaque psoriasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}